CCI
MCRB icon

Columbus Circle Investors’s Seres Therapeutics MCRB Stock Holding History

Columbus Circle Investors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$3.8M Buy
+7,750
New +$4.54M 0.17% 111
2016
Q3 		– Sell
-18,375
Closed -$10.7M – 289
2016
Q2 		$10.7M Buy
+18,375
New +$10.8M 0.11% 164

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Columbus Circle Investors's MCRB Position: Q4 2020 in Review

Columbus Circle Investors opened a new position in Seres Therapeutics (MCRB) in Q4 2020: 7,750 shares worth $3.8M. The stake represents 0.17% of the portfolio and ranks #111 among its holdings. This is a return to the name: Columbus Circle Investors previously reported a position in MCRB as recently as Q2 2016.

Columbus Circle Investors first reported a position in MCRB in Q2 2016 and has held it in 2 quarters since. The position peaked at $10.7M in Q2 2016. 152 funds tracked by Wall St. Rank hold MCRB as of Q4 2020.

  • Columbus Circle Investors held 7,750 shares of Seres Therapeutics worth $3.8M as of Q4 2020.
  • Seres Therapeutics was a new Columbus Circle Investors position in Q4 2020.
  • Seres Therapeutics made up 0.17% of Columbus Circle Investors's portfolio in Q4 2020, its #111 holding.
  • Columbus Circle Investors first reported a position in Seres Therapeutics in Q2 2016 and has held it in 2 quarters since.
  • Columbus Circle Investors's Seres Therapeutics position peaked at $10.7M in Q2 2016.
  • 152 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2020.

Based on Columbus Circle Investors's 13F filing for Q4 2020, filed 20 Jan 2021.